ArticleHemodialysis international. International Symposium on Home Hemodialysis2026
Long Term Outcome of Brachial-Basilic Arteriovenous Fistulas.
Article in Hemodialysis international. International Symposium on Home Hemodialysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAutogenous arteriovenous fistulas are the preferred vascular access for hemodialysis due to superior patency and lower infection rates compared with grafts or catheters. The brachiobasilic AV fistula provides a valuable option for patients with unsuitable veins, though it remains underutilized due to technical challenges and wound morbidity. This study aimed to evaluate the clinical outcomes, patency, and complications of brachiobasilic-AV fistula creation over a 10-year period at a tertiary vascular center.
methodsA retrospective descriptive analysis was conducted of all patients who underwent brachiobasilic AV fistula creation between January 2014 and December 2024 at the Manmohan Cardiothoracic Vascular and Transplant Center. Demographics, comorbidities, operative details, and outcomes were obtained from hospital records and follow-up interviews. Preoperative vessel diameters were assessed using Doppler ultrasonography. Brachiobasilic AV fistulas were created using either single-stage (82.6%) or two-stage (17.4%) techniques. Statistical analysis was performed to assess maturation, patency, and complication rates (p < 0.05 considered significant).
resultsA total of 167 brachiobasilic AV fistulas were created in 158 patients (62 males, 96 females; mean age 55.6 ± 15.8 years). The most common comorbidities were hypertension (91.1%) and diabetes (49.4%). The mean basilic vein and brachial artery diameters were 3.46 ± 1.6 mm and 3.23 ± 0.8 mm, respectively. Successful maturation occurred in 141 cases (84.4%) within 6 weeks, while 21 (12.6%) experienced early failure. Primary patency was 22 ± 5 months, and secondary patency was 6 ± 2.1 months. Kaplan-Meier analysis demonstrated primary patency rates of 98%, 65%, and 28% at 1, 3, and 5 years, respectively. The most frequent complications included bleeding (40.7%), infection (12.6%), and pseudoaneurysm (11.4%).
conclusionFor the patients with exhausted autogenous vascular access, brachiobasilic AV fistula is a viable procedure in our setting with acceptable complication and patency outcomes comparable to international standards. Outcome and postoperative complication can be reduced by adoption of newer techniques which need further evaluation considering cost and benefit issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.